Treatment-Resistant Depression (TRD): For individuals who haven't found relief after trying at least two different antidepressants.
Major Depressive Disorder (MDD) with Acute Suicidal Ideation or Behavior: A fast-acting option for those experiencing severe symptoms and urgent need.
Unlike traditional antidepressants, which can take weeks to work, SPRAVATO® has shown rapid improvements in depressive symptoms—often within 24 hours.
SPRAVATO® takes a novel approach to managing depression. Administered under the supervision of a healthcare provider, this nasal spray targets NMDA receptors in the brain, leading to quick and significant symptom relief. SPRAVATO® works through the glutamate system, the brain’s most abundant excitatory neurotransmitter, helping promote the formation of new neural connections through neuroplasticity—effectively helping reset disrupted brain patterns associated with depression.
Patients receive SPRAVATO® in our REMS-certified treatment center in Wyckoff, New Jersey, where they are closely monitored for at least two hours post-administration by our experienced medical team.
SPRAVATO® may be covered by insurance as it’s FDA-approved for treatment-resistant depression. Coverage varies significantly by insurance plan, so we recommend contacting your insurance provider to verify your benefits. We can provide the necessary documentation and work with your insurance company to facilitate coverage.
For patients without insurance coverage or with high out-of-pocket costs, manufacturer assistance programs may be available. We’ll help you explore all options to make treatment accessible.
Begin with a complimentary phone consultation, followed by an in-depth evaluation by our mental health professionals. We review your medical history, treatment history, and current symptoms to confirm eligibility for SPRAVATO®. If eligible, we verify your insurance coverage.
Once approved, your initial SPRAVATO® session is scheduled at our Wyckoff clinic. You self-administer the nasal spray under strict medical supervision in our comfortable treatment rooms. You are monitored for at least two hours, with blood pressure checked before and after treatment.
Your treatment begins with twice-weekly sessions for the first 4 weeks. This transitions to weekly sessions for weeks 5-8, then every other week or less frequently—customized to your response and needs. Your treatment plan is adjusted based on your unique mental health goals.
Our team remains by your side with regular follow-ups to monitor progress and address concerns. We adjust your treatment plan as needed and coordinate with your referring provider. We serve patients throughout northern New Jersey, including Franklin Lakes, Ridgewood, Ramsey, Wayne, and Paramus.
Week 1-4
2 Treatments a Week
Week 5-8
1 Treatments a Week
Week 9+
1 Treatment Every 1-2 Weeks
Response Rate: Traditional antidepressants typically show a response rate of 40–60%, while SPRAVATO® (esketamine) has demonstrated response rates of up to 70% in clinical trials.
Time to Noticeable Effect: Traditional antidepressants often take 4–6 weeks for noticeable improvements, whereas patients using SPRAVATO® (esketamine) may experience relief within 24 hours, as observed in clinical trials.
Sustained Remission Rate: Traditional antidepressants achieve sustained remission rates of approximately 15–30%, but SPRAVATO® has shown remission rates as high as 80% when combined with an oral antidepressant.
As a REMS-certified SPRAVATO® provider, Ketavita follows rigorous FDA-approved treatment protocols. All providers are specially trained and certified. Effective, safe, uplifting.
The setting—the place you actually receive treatments—is part of your healing process. Our comfortable treatment rooms in Wyckoff are designed to support your healing.
If you already have an existing mental health team, we want to ensure they're in the loop—so you can receive the best possible care, all around.
If the cure involves high costs and paperwork, it's not a cure. We work to verify insurance coverage and help you explore manufacturer assistance programs to make SPRAVATO® treatment accessible.
Explore the inspiring journeys of individuals who have transformed their lives through the clinical use of SPRAVATO®. From overcoming obstacles to reaching significant milestones, these individuals share how SPRAVATO® treatment has been instrumental in reshaping their habits and creating lasting change. Discover real-life stories of success, motivation, and the powerful impact of building sustainable habits for a better life.
Over 3,000+ residents have used SPRAVATO® to elevate their lives.
Clinical studies show that patients who respond to SPRAVATO® and continue maintenance treatment have significantly lower relapse rates compared to those who discontinue. Ongoing treatment helps sustain therapeutic benefits.
If you’ve been struggling with treatment-resistant depression despite trying multiple antidepressants, SPRAVATO® at Ketavita Wellness Clinic may offer the breakthrough you’ve been seeking with FDA approval and possible insurance coverage.
Call us at (201) 588-6471 or contact us online to schedule your free consultation.
Correia B, Balhara R, Williams M. Exploring Esketamine's Therapeutic Outcomes as an FDA-Designated Breakthrough for Treatment-Resistant Depression and Major Depressive Disorder With Suicidal Intent: A Narrative Review. Cureus. 2024;16(2):e54693. https://pmc.ncbi.nlm.nih.gov/articles/PMC10928016/
Acevedo-Diaz EE, Cavanaugh GW, Greenstein D, et al. Esketamine for treatment‑resistant depression: A review of clinical evidence. Experimental and Therapeutic Medicine. 2023;25(3):111. https://pmc.ncbi.nlm.nih.gov/articles/PMC9922941/